Compare Equinor ASA (EQNR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Sana Biotechnology Inc — how do they compare? Equinor ASA trades at $43.01 (market cap $101.62B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Equinor ASA is far larger — about 121.5× Sana Biotechnology Inc's market cap, and Equinor ASA pays a 3.63% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Sana Biotechnology Inc for 23 Days on average.
| EQNR | SANA | |
|---|---|---|
Market Cap | $101.62B | $836.71M |
Volume | 4,991,782 | 4,507,444 |
Sector | Energy | Health |
52-Week High | $45.75 | $5.92 |
52-Week Low | $22.41 | $2.68 |
Typical Hold Time | 59 Days | 23 Days |
Enterprise Value | $110.31B | $749.96M |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $42.93, up 3.17% today, with a bullish technical signal and strong valuation metrics including a P/E of 11.63 and EV/EBITDA of 2.39. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company maintains robust cash flow from operations at $20.0 billion in 2025 and has announced dividends and share buy-backs, reflecting financial health.
The outlook is positive with a consensus price target of $87.50, implying significant upside. Key opportunities include LNG expansion plans and cost efficiency, while risks involve volatile energy prices and execution challenges. Analyst sentiment is mixed but leans bullish, supported by strong institutional interest and strategic growth initiatives.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
